Other Events ·
Clearmind Medicine Inc. issued a press release on July 17, 2026, noting regulatory and inter-agency developments…
CMNDClearmind Medicine Inc.
Clearmind Medicine Inc. issued a press release on July 17, 2026, noting regulatory and inter-agency developments supporting psychedelic-based therapies. These developments include final FDA guidance on psychedelic clinical investigations, a planned public hearing, and new collaborative initiatives involving the U.S. Department of Health and Human Services, Department of Veterans Affairs, and FDA. Clearmind Medicine is a clinical-stage biotechnology company developing non-hallucinogenic neuroplastogen-derived treatments for Alcohol Use Disorder, addiction, and weight management.